@misc{misc, title  = {{26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)}},

 url = {{}},

 year = {{2021}},

 month = {{9}},

 author = {{Cork MJ and Thaçi D and Eichenfield L and Arkwright PD and Chen Z and Delevry D and O’Malley JT and Bansal A}},

 note = {{Accessed on 2024/12/22}}}